Catalyst Pharmaceuticals, Inc.
CPRX
$23.10
$0.482.12%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 578.20M | 558.50M | 534.65M | 491.73M | 460.48M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 578.20M | 558.50M | 534.65M | 491.73M | 460.48M |
| Cost of Revenue | 97.52M | 94.77M | 88.19M | 81.49M | 73.83M |
| Gross Profit | 480.67M | 463.73M | 446.46M | 410.24M | 386.65M |
| SG&A Expenses | 184.52M | 182.93M | 177.71M | 177.74M | 175.58M |
| Depreciation & Amortization | 37.38M | 37.38M | 37.38M | 37.38M | 37.09M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 319.42M | 315.08M | 303.28M | 296.61M | 286.51M |
| Operating Income | 258.78M | 243.42M | 231.37M | 195.12M | 173.97M |
| Income Before Tax | 285.80M | 271.97M | 258.46M | 216.26M | 188.79M |
| Income Tax Expenses | 68.23M | 63.30M | 61.11M | 52.37M | 45.99M |
| Earnings from Continuing Operations | 217.56 | 208.67 | 197.35 | 163.89 | 142.80 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 217.56M | 208.67M | 197.35M | 163.89M | 142.80M |
| EBIT | 258.78M | 243.42M | 231.37M | 195.12M | 173.97M |
| EBITDA | 296.57M | 281.25M | 269.17M | 232.90M | 211.43M |
| EPS Basic | 1.79 | 1.73 | 1.65 | 1.38 | 1.24 |
| Normalized Basic EPS | 1.45 | 1.37 | 1.30 | 1.11 | 1.01 |
| EPS Diluted | 1.72 | 1.65 | 1.57 | 1.31 | 1.18 |
| Normalized Diluted EPS | 1.39 | 1.30 | 1.24 | 1.05 | 0.96 |
| Average Basic Shares Outstanding | 486.13M | 482.46M | 478.48M | 473.81M | 460.63M |
| Average Diluted Shares Outstanding | 507.87M | 506.19M | 503.30M | 499.75M | 487.22M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |